| Title: | Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin |
| Authors: | Miya, Aika Browse this author |
| Nakamura, Akinobu Browse this author →KAKEN DB |
| Cho, Kyu Yong Browse this author |
| Kawata, Shinichiro Browse this author |
| Nomoto, Hiroshi Browse this author →KAKEN DB |
| Nagai, So Browse this author →KAKEN DB |
| Sugawara, Hajime Browse this author |
| Taneda, Shinji Browse this author |
| Tsuchida, Kazuhisa Browse this author |
| Omori, Kazuno Browse this author |
| Yokoyama, Hiroki Browse this author |
| Takeuchi, Jun Browse this author |
| Aoki, Shin Browse this author |
| Kurihara, Yoshio Browse this author |
| Atsumi, Tatsuya Browse this author →KAKEN DB |
| Miyoshi, Hideaki Browse this author →KAKEN DB |
| Keywords: | glucose variability |
| C-peptide |
| sodium–glucose co-transporter 2 inhibitor |
| Issue Date: | 10-Aug-2021 |
| Publisher: | John Wiley & Sons |
| Journal Title: | Journal of Diabetes Investigation |
| Volume: | 12 |
| Issue: | 8 |
| Start Page: | 1395 |
| End Page: | 1399 |
| Publisher DOI: | 10.1111/jdi.13479 |
| Abstract: | Aims/Introduction To identify the effect of combination therapy with a dipeptidyl peptidase‐4 (DPP‐4) inhibitor and a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor compared with switching from a DPP‐4 inhibitor to a SGLT2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. Materials and Methods A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was conducted in a multicenter, prospective, randomized, parallel‐group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C‐peptide (CPR) divided at baseline by the median. Results ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (-29.2±28.3 vs. -20.0±24.6, respectively; P=0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group (P<0.01). Conclusions COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion. |
| Rights: | http://creativecommons.org/licenses/by/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/82877 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
